Iizuka-shi
Iizuka-shi
Iizuka-shi, Japan10 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis | Skin and Connective Tissue Diseases, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, immune system disorder, musculoskeletal system disorder, rheumatic disorder, rheumatoid arthritis | Recruiting | Phase 2 | 2026-10-09 | NCT07276581 | |
| A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, cardiovascular disorder, chronic renal failure syndrome, hypertensive disorder, kidney disorder, kidney failure, urinary system disorder, vascular disorder | Recruiting | Phase 3 | 2026-09-25 | NCT06742723 | |
| A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Active, not recruiting | Phase 3 | 2026-09-25 | NCT05197049 | |
| Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 3 | 2026-09-03 | NCT06921785 | |
| Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) | Non Small Cell Lung Carcinoma NSCLC | Active, not recruiting | Phase 3 | 2026-08-06 | NCT02542293 | |
| Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-08-06 | NCT02453282 | |
| Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Nutritional and Metabolic Diseases, hereditary disease, hypophosphatasia, inborn errors of metabolism, inborn metal metabolism disorder, metabolic disease | Active, not recruiting | Phase 3 | 2026-06-22 | NCT06079281 | |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis | Fibrosis, Hemic and Lymphatic Diseases, Hypersensitivity, Delayed, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, diffuse scleroderma, immune system disorder, interstitial lung disease, lung disorder, lymphatic system disorder, lymphoproliferative syndrome, musculoskeletal system disorder, pulmonary fibrosis, respiratory system disorder, rheumatic disorder, rheumatoid arthritis, sarcoidosis, skin disorder, systemic sclerosis | Active, not recruiting | Phase 3 | 2026-04-23 | NCT06025578 | |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis | Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-03-24 | NCT06003426 | |
| Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB) | Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms | Recruiting | Phase 2 | 2025-11-10 | NCT07048262 |